We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Exposure to Toxins in Children Associated with Kidney Disease Biomarker

By LabMedica International staff writers
Posted on 26 Jul 2016
Image: New research shows children living in Mexico who are exposed to multiple toxins evidence a higher incidence of chronic kidney disease (Photo courtesy of BWH).
Image: New research shows children living in Mexico who are exposed to multiple toxins evidence a higher incidence of chronic kidney disease (Photo courtesy of BWH).
Researchers have assessed environmental exposure to multiple toxins in children living in a region of Mexico with a high incidence of chronic kidney disease, especially among young adults. They not only detected high levels of arsenic and chromium in urine samples, they also detected elevated levels of Kidney Injury Molecule-1 (KIM-1), a biomarker currently being studied as an early sign of kidney injury.

Exposure to environmental toxins – such as arsenic, cadmium, chromium, lead, and other heavy metals – early in life via contaminated water or other sources often have long-term health consequences as children grow. Investigators at Brigham and Women's Hospital (BWH; Boston, MA, USA) and Harvard Medical School (Boston, MA, USA) have found exceedingly high levels of arsenic and chromium in urine samples collected from 107 children living in the north-central region of Mexico – levels that were even higher than exposure limits set for adults. When the team measured traditional biomarkers of kidney function – such as those measured at a routine physical exam – they did not find elevated levels of these markers. However, more sensitive and specific biomarkers of kidney injury recently qualified by the FDA for use in preclinical studies, e.g. KIM-1, were elevated in the children. KIM-1 might serve as a sensitive biomarker to screen children for kidney damage induced by environmental toxic agents.

“Until now, no one has studied these children – an especially vulnerable population – to determine their risk of exposure and possible measures of kidney dysfunction,” said senior author Vishal Vaidya, PhD, of BWH and Harvard, “KIM-1 may be an early warning sign of exposure, suggesting that something may be beginning to go wrong in the epithelial cells in the kidneys of these children. Many questions remain to be answered. We don’t know if this effect might be reversible, we don’t know if there are other kidney toxic contaminants such as uranium present as well. Because we don’t have follow-up data from these children we also don’t know the long-term consequences of this exposure. But this does give us our first insights into this population at a young age.”

“For the first time, we’ve been able to evaluate and assess an early warning sign of kidney injury – one that may give us the ability to act in advance before there is irreversible harm,” said first author Mariana Cardenas-Gonzalez, PhD, postdoctoral fellow in the Vaidya lab, “This may be a problem that can be solved by reducing exposure, but first we need to understand how such high levels of these toxins are winding up in the urine of these children.”

The research team also tested water samples from the children’s tap water, identifying contaminated drinking supply as the likely source of arsenic. The source of chromium, however, remains unknown so further investigation is needed. Chromium exposure can come from contaminated air, soil, water, food, or tobacco products.

The study, by Cardenas-Gonzalez M et al, was published online July 15, 2016, in the journal Environmental Research.

Related Links:
Brigham and Women's Hospital
Harvard Medical School

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Homocysteine Quality Control
Liquichek Homocysteine Control

Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more